Overview: CD23 Flow Cytometry TestIntroduction: The CD23 Flow Cytometry Test detects CD23 markers to diagnose chronic lymphocytic leukemia, causing fatigue or infections. Aligned with 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected chronic lymphocytic leukemia.
Other Names: CD23 Flow Assay, Fc Epsilon Receptor Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: CD23 testing began in the 1990s with leukemia research. Flow cytometry panels emerged in the 2000s, improving accuracy for CLL diagnosis.
Purpose: Diagnoses chronic lymphocytic leukemia, guides treatment, and monitors CD23 markers in patients with fatigue or infections.
Test Parameters: 1. CD23
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fatigue or infections, and list medications.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, frequent infections, or history of chronic lymphocytic leukemia. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses flow cytometry to detect CD23 markers. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Non-malignant conditions may express CD23.
Clinical Significance: Positive CD23 expression suggests chronic lymphocytic leukemia, prompting treatment. Negative results may require additional marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, other flow cytometry markers (e.g., CD5, CD19), or FISH to confirm CLL.
Test Limitations: Non-specific expression may occur in non-malignant conditions. Results require clinical correlation.
References: ASH Leukemia Guidelines, 2023; Blood, Arber DA, 2022.
